Clinical trials
Refractory Diffuse Large B-Cell Lymphoma clinical trials
Below are recruiting refractory diffuse large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 195 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06618313Recruiting
Testing JCXH-213 for B-cell lymphoma that returned or didn't respond
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
BeijingAges 18 years+ - NCT05869279RecruitingPhase 1/Phase 2
Study of donor immune cells for B-cell blood cancers
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Bergamo, BGAges 1 year+ - NCT06570447RecruitingPhase 2
Glofitamab and chidamide for relapsed or refractory DLBCL
This trial tests a combination of two drugs, glofitamab and chidamide, for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded after at least two prior treatments. The goal is to see if this combination can help when other options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07240194RecruitingPhase 2
A study of a new drug combo for large B-cell lymphoma with TP53 changes
This trial tests a combination of three drugs (glofitamab, a PD-1 antibody, and lenalidomide) for people with relapsed or refractory large B-cell lymphoma that has a TP53 change. The goal is to see if this combination works better for patients who cannot have a stem cell transplant.
Nanjing, JiangsuAges 18 years+ - NCT06689917Recruiting
JY231 injection for relapsed B-cell lymphoma or leukemia
This trial tests a new cell therapy called JY231 for people whose B-cell lymphoma or leukemia has come back or not responded to standard treatments. The therapy targets a protein on cancer cells called CD19 and may help your immune system fight the cancer.
Wuhan, HubeiAges 18–75 - NCT07309900RecruitingPhase 1
Testing IASO208 for relapsed or hard-to-treat B-cell cancers
This trial tests a new treatment called IASO208 for people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. It aims to see if the drug can help shrink tumors and control the cancer.
Wuhan, HubeiAges 18–75 - NCT06996132RecruitingPhase 2
Combination treatment for aggressive B-cell lymphoma that has returned
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
TianjinAges 18–65 - NCT06931652RecruitingPhase 2
Epcoritamab with lenalidomide and rituximab for CNS lymphoma
This trial tests a new combination of drugs—epcoritamab, lenalidomide, and rituximab—for people with primary central nervous system lymphoma (PCNSL) that has come back or not responded to treatment. The goal is to see if this three-drug therapy can help control the cancer.
BordeauxAges 18 years+ - NCT06321289RecruitingPhase 1/Phase 2
Donor T cell therapy for B-cell lymphoma
This trial tests a new type of therapy where specially designed donor T cells target your lymphoma. It's for people with certain B-cell non-Hodgkin lymphomas that have not responded to or returned after standard treatments. You might join if you meet the health and disease criteria listed below.
Beijing, Beijing MunicipalityAges 18–75 - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06489808RecruitingPhase 2
Linperlisib plus chemoimmunotherapy for relapsed large B-cell lymphoma
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07321301RecruitingPhase 2
CAR T-cell therapy for relapsed B-cell lymphoma or leukemia
This trial tests a new type of CAR T-cell therapy for people with B-cell lymphoma or leukemia that has not responded to standard treatments. The therapy uses a special delivery system to help the cells target and kill cancer cells.
Beijing, Beijing MunicipalityAges 14–85 - NCT07240974RecruitingEarly Phase 1
Study of ZZSW-01 for B-cell blood cancers that returned or didn't respond
This trial tests a new drug called ZZSW-01 for people with certain B-cell blood cancers (like lymphoma or leukemia) that have come back or haven't gotten better after other treatments. It aims to see if the drug is safe and works against these cancers.
WuhanAges 18 years+ - NCT07259070RecruitingPhase 1/Phase 2
CAR T-cells targeting BAFF-R for resistant B-cell lymphoma
This trial tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack a protein called BAFF-R on your lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded well to at least two earlier treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06116110Recruiting
Long-term follow-up after gene therapy treatment
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
Gilbert, ArizonaAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Gilbert, ArizonaAges 18 years+ - NCT07197307RecruitingPhase 2
Study of two targeted drugs for relapsed aggressive B-cell lymphoma
This study tests a new combination of two drugs—loncastuximab tesirine (an antibody-drug conjugate) and epcoritamab (a bispecific antibody)—for people whose aggressive B-cell lymphoma has returned or not responded to prior treatment. The goal is to see if the combination is safe and effective.
AachenAges 18 years+ - NCT05365659RecruitingPhase 1
Testing IKS03 for advanced B-cell lymphoma
This trial tests a new study drug, IKS03, for people with advanced B-cell non-Hodgkin lymphoma that has not responded to at least two prior treatments. The goal is to see if the drug is safe and how well it works.
Baltimore, MarylandAges 18 years+ - NCT07620314RecruitingPhase 1
Testing a new cell therapy for B-cell lymphoma
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT05052528RecruitingPhase 1
CAR T cell therapy for relapsed or refractory large B-cell lymphoma
This trial tests whether adding a targeted antibody (rituximab) before CAR T cell therapy improves outcomes for patients with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments.
Sacramento, CaliforniaAges 18 years+ - NCT06565689RecruitingPhase 1
YK012 for B-cell non-Hodgkin lymphoma after prior treatments
This study tests a new daily pill called YK012 for people with certain types of B-cell non-Hodgkin lymphoma that have not responded to at least two prior treatments. The goal is to see if it is safe and if it can shrink tumors.
Beijing, Beijing MunicipalityAges 18–65 - NCT03223610RecruitingPhase 1/Phase 2
ViPOR treatment for relapsed or hard-to-treat lymphoma
This Phase 1/2 trial tests a combination of several medicines (venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid) for lymphoma that has come back or did not respond. It aims to shrink tumors safely and improve responses in people with specific types of B-cell lymphoma.
Bethesda, MarylandAges 18–120 - NCT03418038RecruitingPhase 2
Vitamin C with chemotherapy for certain relapsed blood cancers
This Phase 2 trial tests whether intravenous vitamin C (ascorbic acid) added to chemotherapy can improve outcomes for people with certain relapsed or treatment-resistant lymphomas or chronic myelomonocytic leukemia (CMML). It may help by boosting chemotherapy’s effectiveness and/or changing how the cancer responds.
Mankato, MinnesotaAges 18 years+ - NCT03676504RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed CD19 blood cancers
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
HeidelbergAges 3 years+
Hear when a new Refractory Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory diffuse large b-cell lymphoma?
- Yes. Clin2 currently lists 195 recruiting refractory diffuse large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory diffuse large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory diffuse large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Relapsed/Refractory Large B-Cell Lymphoma
- Refractory Large B-cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.